Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

When to Give Antivirals to Liver Transplant Patients

Clin Gastroenterol Hepatol; ePub 2017 Jun 17; Samur, et al

Publish date:: July 22, 2017

Patients with cirrhosis and hepatitis C who are waiting for a liver transplant fare better with pre-liver transplant administration of direct acting antivirals if they have lower Model for End Stage Liver Disease (MELD) scores, suggests a recent mathematical model. Details of the analysis are as follows:

Quality-adjusted life years (QALYs) were higher in patients with MELD scores at or below 21 if they were given direct acting antivirals before transplantation.
On the other hand, DAAs were more cost effective/saving in patients with MELD scores at or above 22 when administrated after the surgery.

Citation:

Samur S, Kues B, Ayer T, et al. Cost-effectiveness of pre- versus post-liver transplant hepatitis C treatment with direct-acting antivirals. [Published online ahead of print June 17, 2017]. Clin Gastroenterol Hepatol. doi:10.1016/j.cgh.2017.06.024.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Endoscopic intragastric balloon improved NASH parameters,

Autologous fecal microbiota transplantation helped maintain weight loss after ‘green’ Mediterranean diet,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,

Must Reads in Liver Disease

Endoscopic intragastric balloon improved NASH parameters,

Lusutrombopag found safe, effective for severe thrombocytopenia in patients with hepatocellular carcinoma,

Bariatric surgery achieved long-term resolution of NASH without worsening fibrosis,

Anti-CD8a, anti-IL-17A antibodies improved immune disruption in mice with history of NASH,

Studies eyes risks for poor outcomes in primary sclerosing cholangitis,